Cancer Center Support Grant (CCSG)

 描述（由申请人提供）：新重组的癌症基因和途径（CGP）计划中的癌症基因和途径研究侧重于研究生物学上重要的遗传改变和构成癌症发展和免疫监视基础的分子途径。该基础科学计划的主要目标是更好地了解肿瘤发生和癌症免疫学的基本机制，从而定义可用作疾病生物标志物和/或创新抗癌疗法的新分子实体。这是通过三个重叠的研究主题实现的，这些主题集中在1）基因组组织，调控和癌症基因表达，2）细胞增殖，存活和转化，以及3）肿瘤免疫监视。上一个资助期的主要科学成就包括在理解受损DNA修复和复制机制方面的进展，识别和表征新的肿瘤促进遗传改变和癌症基因网络，开发创新的癌症动物模型，以及确定控制B和T淋巴细胞存活和激活的途径。CGP成员包括54个正式成员和6个准成员，跨越3个学院的16个部门（10个基础科学，6个临床）。在上一个预算年度，CGP用于同行评审研究的年度总资金为1036万美元（2美元NCI资金），非同行评审研究项目为199万美元。CGP成员高度合作，在过去4年中撰写或共同撰写了353篇癌症相关同行评审出版物，其中17%（n=59）为计划内，22%（n=77）为计划间，32%（n=113）为机构间。49篇论文发表在高影响力期刊上（影响因子>10）。富有成效的项目内/项目间和多机构小组在成熟B谱系肿瘤（骨髓瘤和非霍奇金淋巴瘤）和神经内分泌肿瘤研究方面取得了领先进展，并对其他人类恶性肿瘤（包括白血病、乳腺癌、前列腺癌、黑色素瘤、胰腺癌和肝癌）做出了重大贡献。

 DESCRIPTION (provided by applicant): Cancer Genes and Pathways Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of biologically significant genetic alterations and molecular pathways that underlie cancer development and immune surveillance. The primary goal of this basic science program is to better understand fundamental mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2) cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific achievements over the prior funding period include advances in understanding mechanisms of damaged DNA repair and replication, identification and characterization of novel tumor-promoting genetic alterations and cancer gene networks, development of innovative animal models of cancer, and determination of pathways controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding for peer-reviewed research in the last budget year was $10.36 million ($2 NCI funding) and $1.99 million for non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored 353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22% (n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor research, and making major contributions to other human malignancies including leukemias, breast cancer, prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.